<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents

<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents

<i>Background</i>: Reversion mutations in <i>BRCA1/2</i>, resulting in restoration of the open reading frame, have been identified as a mechanism of resistance to platinum-based chemotherapy or PARP inhibition. We sought to explore the incidence of <i>BRCA1/2</i>...

Full description

Bibliographic Details
Main Authors: Sourat Darabi, David R. Braxton, Joanne Xiu, Benedito A. Carneiro, Jeff Swensen, Emmanuel S. Antonarakis, Stephen V. Liu, Rana R. McKay, David Spetzler, Wafik S. El-Deiry, Michael J. Demeure
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Medicina
Subjects:
<i>BRCA1/2</i>
reversion mutations
PARP inhibitors
resistance mechanisms
platinum-based therapy
Online Access:https://www.mdpi.com/1648-9144/58/12/1818

Internet

https://www.mdpi.com/1648-9144/58/12/1818

Similar Items